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SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells
and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute
significantly to the therapeutic activities and that the antitumour effects of SGN-40 depend on Fc interactions.
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CD40 is a member of the tumour necrosis factor (TNF) receptor
superfamily and is expressed predominantly on haematopoietic
cells, including B-cells, dendritic cells, monocytes, macrophages,
activated B-cells and CD8þ T-cells (reviewed in van Kooten and
Banchereau (2000)). In lymphoid malignancies, CD40 is present on
B-cell precursor acute lymphoblastic leukaemia (ALL (Uckun et al,
1990)), non-Hodgkin’s lymphoma (NHL (Uckun et al, 1990)),
Hodgkin’s lymphoma (HL (O’Grady et al, 1994)) and multiple
myeloma (MM (Westendorf et al, 1994)).
The humanised monoclonal antibody targeting CD40 (SGN-40)
induces potent antitumour effects when tested on CD40-positive
tumour cell lines representing a variety of haematologic malig-
nancies (Tai et al, 2004; Law et al, 2005). The mechanisms
mediating the antitumour activity of SGN-40 include direct
cytotoxic signalling, inducing caspase-3 activation and apoptosis
of tumour cells (Law et al, 2005; Tai et al, 2005) and natural killer
(NK) cell-mediated ADCC. Both, direct cell killing and NK cell-
mediated ADCC are enhanced by antibody crosslinking (Law et al,
2005) when tested in vitro. However, the mechanism involved in
mediating anti-lymphoma activity of SGN-40 in vivo remained to
be investigated.
The ability of several human IgG1-type therapeutic antibodies to
engage human effector cells varies significantly, depending on the
target antigen and tumour type, and variable degrees of tumour
cell death induced by NK cells, neutrophils and macrophages were
reported for anti-CD19, -20 and -70 antibodies (reviewed in Tedder
et al (2006)). Here we show for the first time that macrophages
contribute significantly to the antitumour effects of SGN-40 when
tested in models of human lymphoma. In addition, a mutant form
of SGN-40, lacking Fc-receptor interactions (SGN40-IgG1v1),
lacked therapeutic activity when tested in vitro and in mice
implanted with B-cell lymphomas. The important role of macro-
phages in mediating therapeutic activity described here may help
to guide the clinical development of SGN-40 for the treatment of
B-cell malignancies.
MATERIALS AND METHODS
Cells and reagents
The CD40-positive lymphoma cell lines Ramos (NHL, Burkitt’s
lymphoma) and WIL2-S (B-cell lymphoma) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA,
USA). The CD40-negative cell line L540cy was kindly provided by
Dr Phil Thorpe (University of Texas, Southwestern Medical School,
Dallas, TX, USA). Cells were grown in RPMI (Life Technologies
Inc., Gaithersburg, MD, USA) supplemented with 20% fetal bovine
serum (FBS).
Construction and expression of SGN-40G1v1 variant
antibody and Fcc receptors
The anti-CD40 variant containing the mutations, E233P:
L234V:L235A (Armour et al, 1999) (SGN-40G1v1) was generated
using the Quikchange Site-Directed Mutagenesis system (Strata-
gene, La Jolla, CA, USA). The SGN-40 variant heavy chain and
SGN-40 light chain were each cloned into the expression vector
pDEF38 (Running Deer and Allison, 2004) downstream of the
CHEF EF-1a promoter and stably expressed in CHO-DG44 (Urlaub
et al, 1986) cells. SGN-40 and SGN-40G1v1 proteins were expressed
in CHO-DG44 cell lines and purified by protein A chromato-
graphy. Complementary DNA clones for human (hu) FcgRI
(IMAGE clone 5248549), huFcgRIIIA V158 (IMAGE clone
5206097) and huFceR g chain (IMAGE clone 5219148) were
obtained from Invitrogen (Carlsbad, CA, USA) and coding regions
were introduced into a mammalian expression vector system.
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sProteins were expressed in CHO-DG44 cell lines and highly
expressing clones were selected by FACS and recovered by limited
dilution cloning. Preliminary pharmacokinetic analysis of serum
samples from treated mice revealed comparable characteristics
between SGN-40 and SGN-40G1v1 (data not shown).
In vitro characterisation of antibody binding
SGN-40 was labelled with Alexa Fluor 488 carboxylic acid–
succinimidyl ester conjugation using the Invitrogen Alexa Fluor
488 labeling kit (Invitrogen). For binding experiments, Ramos
or stable CHO DG-44 cells expressing huFcgRI and huFcgRIIIA
V158 were mixed and combined with serial dilutions of SGN-40
or the SGN-40G1v1 variant. Labelled cells were detected using
an LSRII FACS analyzer (Beckton Dickinson Biosciences, San Jose,
CA, USA). The flow cytometry data was analysed with a one
site competition model equation using Prism v4.01 (GraphPad
Software, San Diego, CA, USA).
Antibody-dependent cellular phagocytosis assay
The assay was performed as described earlier (McEarchern et al,
2007). Briefly, after labelling of CD40-positive target cells (Ramos),
cells were pre-coated with SGN-40 or SGN-40G1v1 and incubated
with monocyte-derived macrophages. The purity of the macro-
phage preparations were routinely 495% (data not shown).
Xenograft models and effector cell ablation and IHC
analysis
Tumour bearing CB-17/lcr SCID mice were depleted of effector
cells by using anti-asialo-GM 1 (1.25mgkg
 1, neutrophils) and
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Figure 1 SGN-40 mediates antibody-dependent cellular phagocytosis (ADCP) activity and requires functional Fc–FcgR interaction in vitro.( A) Binding of
SGN-40 and SGN-40G1v1 to CD40þ Ramos cells was detected by flow cytometry. EC50 values are 0.510 and 0.528nM for SGN-40 and SGN-40G1v1,
respectively. (B) Binding of SGN-40 and SGN-40G1v1 to CHO DG-44 cell lines expressing human or mouse FcgRI (CD64) and FcgRIIIA V158 (CD16) as
determined by flow cytometry. Data is reported as the percent of maximum fluorescence, calculated by the sample fluorescence divided by the fluorescence
of cells stained with anti-CD40-Alexa Fluor 488. NMB¼non-measurable binding. (C) SGN-40 induces ADCP activity in vitro as determined by flow
cytometry and fluorescence microscopy. Ramos target cells were labelled with PKH26 lipophilic dye for tracking purposes, and treated with non-binding
control IgG or SGN-40 MAb and mixed with human monocyte-derived macrophages (Mø). Mø were stained with PE-conjugated anti-CD11b. Cells present
in the upper right quadrant (PKH26þCD11bþ) are Mø that internalised tumour cells. For fluorescence microscopy, tumour cells were labelled with
PKH67 (green) and the macrophages were detected with Alexa Fluor 568-conjugated antibody specific for CD11b (red). No ADCP activity was detected
on control, CD40-negative Hodgkin’s lymphoma (HL) cells L540cy (D) CD40-positive Ramos, WIL2-S and the CD40-negative L540cy target cells were
labelled with PKH26 lipophilic dye, treated with varying concentrations of SGN-40, SGN-40G1v1 or non-binding control IgG then mixed with Mø.
(E) Survival curve of mice implanted with Ramos tumour cells and left untreated or following treatment with 4mgkg
 1 SGN-40 or SGN-40G1v1 on day 1
(n¼10 per group), untreated vs SGN-40 (Po0.0001), untreated vs SGN-40G1v1 (P¼0.7190), SGN-40 vs SGN-40G1v1 (Po0.0001). Data shown are
from one representative of a total of two independent experiments.
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 1, NK cells) clodronate encapsuled liposomes
(CEL, macrophage), as described earlier (Oflazoglu et al, 2007). For
IHC analysis, liver and spleen sections were stained with an anti-
mouse F4/80 (macrophage marker) (AbD Serotec, Oxford, UK)
using the Bondmax autostainer (Leica Microsystems Inc.,
Bannockburn, IL, USA) with an alkaline phosphatase-fast red
detection kit. Mice were monitored at least twice per week and
were sacrificed when they exhibited signs of disease, including
weight loss of 15–20%, hunched posture, lethargy, cranial swelling
or dehydration. Statistical analysis was conducted using the
log-rank test with the Graphpad Prism Software Package version
4.01 (Graphpad). All animal experiments were performed accord-
ing to the guidelines of the Institutional Animal Care and Use
Committee (IACUC).
RESULTS AND DISCUSSION
To study the contributions of Fc-receptor interactions to the
antitumour activity of SGN-40, we constructed an Fc variant form
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Figure 2 Macrophages mediate antitumour activity of SGN-40 and requirement for intact Fc–FcgR interactions in vivo.( A) Mice implanted with Ramos
tumours (NHL) were depleted of natural killer cells ( NK) (B) neutrophils ( Neut), (C) macrophages ( Mac) or (D) all subsets combined ( All). Mice
were either left untreated or treated with 4mgkg
 1 SGN-40 on day 1 post tumour implantation (n¼10 per group), using intraperitoneal injections.
Untreated vs SGN-40 (Po0.0001), untreated vs  NKþSGN-40 (Po0.0001), SGN-40 vs  NKþSGN-40 (P¼0.4611). Untreated vs  NeutþSGN-40
(P¼0.0001), SGN-40 vs  NeutþSGN-40 (P¼0.5969). Untreated vs  MacþSGN-40 (P¼0.002), SGN-40 vs  MacþSGN-40 (P¼0.0016). Untreated
vs All depleted (P¼0.0594), SGN-40 vs All depleted þSGN-40 (P¼0.0004). Data shown are from one representative of a total of two or three
independent experiments. (E) FACS analysis of spleen from NK cell-depleted mice using anti-DX5 antibody, or peripheral blood from neutrophil-depleted
mice, using an anti-CD11b antibody. The right panels display IHC analysis of liver tissues isolated from macrophage-depleted mice using an anti-mouse-F4/80
antibody.
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sof SGN-40 containing a substitution of three amino acids in the Fc
portion of the g1 heavy chain (SGN-40G1v1). When introduced to
other therapeutic MAbs of the IgG1 isotype, these changes resulted
in abolished Fc-receptor interactions (Armour et al, 1999). As
expected, no changes in the ability of SGN-40 and SGN-40G1v1 to
bind to CD40 were observed (Figure 1A). However, competition
binding assays with cells expressing human or mouse CD16
(FcgRIII) and CD64 (FcgRI) confirmed that SGN-40G1v1 lacked
binding affinity to Fc receptors (Figure 1B). For SGN-40, weaker
binding to mouse relative to human CD64 (FcgR1) and lack of
binding to mouse CD16 (FcgRIII) were also noticed. Although
Fcg-receptor interactions are essential for effector cell activation,
no direct correlation between binding affinities of therapeutic
antibodies and activation of effector cells were reported (Richards
et al, 2008), because these responses are ultimately regulated by the
balance between activating and inhibitory signals delivered
through Fcg receptors. Therefore, the differences in binding
affinity of SGN-40 between Fcg-RIþIII are not predictive for
antitumour activities in vivo.
To determine the levels of antibody-dependent cellular phago-
cytosis (ADCP) engagement, SGN-40 and SGN-40G1v1 were
incubated in presence of primary human monocytic cells and
tested for their ability to induce phagocytosis of CD40þ Ramos
(Burkitt’s lymphoma, Figures 1C and D) and WIL2-S cells (B-cell
lymphoma, Figure 1D) by macrophages. Although SGN-40 induced
robust ADCP, SGN-40G1v1 was devoid of detectable ADCP
activity, showing that Fc–Fcg-receptor interactions are necessary
for phagocytic uptake of target lymphoma cells (Figure 1D). These
studies show that Fc-dependent ADCP may represent an important
mechanism by which SGN-40 induces anti-lymphoma effects.
To investigate the relevance of Fc–FcgR interactions for overall
therapeutic activity, we compared survival of tumour bearing mice
treated with either SGN-40 or SGN-40G1v1. In contrast to SGN-40,
SGN-40G1v1 did not delay disease progression relative to
untreated mice (Figure 1E). These findings indicate that all
mechanisms contributing to anti-lymphoma activities by SGN-40
are dependent on Fc interactions in this NHL model, including
direct apoptotic signalling in tumour cells. Next, we were
interested to identify the identity of the effector cells mediating
the antitumour activity of SGN-40 in vivo. For this purpose,
tumour-bearing mice were selectively depleted of either NK cells
(Figure 2A), neutrophils (Figure 2B), macrophages (Figure 2C) or
all three cell types combined (Figure 2D). Although the lack of NK
cells and neutrophils did not significantly affect the antitumour
activity of SGN-40, depletion of macrophages, either alone or
combined with NK and neutrophil cells, resulted in decreased
survival of tumour-bearing mice compared with non-effector cell
ablated animals (Figures 2C and D, P¼0.0016 and 0.0004,
respectively). These findings are in agreement with an earlier
report showing potent antitumour activity of SGN-40 in SCID-
beige mice, which display impaired NK cell functions (Law et al,
2005). Antitumour activity was evident in macrophage ablated
mice (Figure 2C), suggesting that non-macrophage-dependent
mechanisms may contribute to the in vivo activity in this model,
including direct apoptotic signalling in tumour cells. The degree of
effector cell depletion was monitored by FACS or IHC analysis
(Figure 2E). Robust target effector cell depletion was confirmed by
flow cytometric analysis of splenocytes (NK cells, anti-DX5),
peripheral blood (neutrophils, anti-CD11b) or by F4/80-IHC
staining (macrophages) in liver sections.
In humans, macrophages express all three Fcg receptors,
whereas neutrophils and NK cells express predominantly FcgRII
and FcgRIII (Koene et al, 1997). Sequence nucleotide polymor-
phisms within the FCGR2 and FCGR3 loci in humans alter their
binding affinities to IgG1 Mabs, and ultimately impact on
downstream effector cell engagement of therapeutic Mabs such
as the anti-CD20 antibody Rituximab (Weng and Levy, 2003). In
addition, the contributions of effector cells to antitumour effects of
therapeutic MAbs were shown to vary between tumour types. For
example, FcgRI I þIII single nucleotide polymorphisms (SNPs)
correlated with therapeutic activity of rituximab in NHL, but not in
CLL patients (Cartron et al, 2002; Weng and Levy, 2003; Farag
et al, 2004). Combined, these findings suggest that the analysis of
patient Fcg-receptor polymorphisms and comparison with clinical
response rates may provide important information regarding
the mechanism of action employed by SGN-40 in different
heme-malignancies, including NHL and MM. Importantly, the
chemotherapy agents used for the treatment of NHL were shown
to interfere differentially with macrophage functions (Marcus and
Hagenbeek, 2007). Given the important role of macrophages in
mediating the therapeutic activity of SGN-40 described in this
report, it is tempting to speculate that combining SGN-40 with
therapeutic agents that enhance macrophage activities, including
Revlimid in MM indications, may be beneficial.
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